... SUNNYVALE Calif. Oct. 15 /- Cepheid (Nasd...Cleared by the FDA for marketing last month Xpert MRSA/SA SSTI is the... The value proposition of Xpert MRSA/SA SSTI is resonating well withp...MRSA is a bacterium that has become resistant to multiple antibiotics...

Cleared by the FDA for marketing last month, Xpert MRSA/SA SSTI is the
first molecular SSTI diagnostic test to receive the moderate complexity
CLIA categorization. With this designation, the test is available for use
inside and outside of the traditional laboratory setting in approximately
6,000 hospitals throughout the U.S.

"The value proposition of Xpert MRSA/SA SSTI is resonating well with
physicians and surgeons -- the healthcare professionals who order tests and
prescribe antibiotics as a part of patient treatment plans," said Cepheid
Chief Executive Officer John Bishop. "With 'Moderate Complexity'
categorization, SSTI test results can be obtained in emergency departments
or other near-patient settings in addition to the central laboratory. The
key benefit is a potential further reduction in the test time-to-result
thereby improving patient management decisions."

MRSA is a bacterium that has become resistant to multiple antibiotics
including penicillin and cephalosporins. Current culture-based lab testing
methods require 24 - 72 hours to determine if a skin or soft tissue
infection is caused by MRSA or SA. As a result, physicians and surgeons
often prescribe broad-spectrum, but often suboptimal, antimicrobial
therapies while awaiting specific culture and susceptibility results.

In less than one hour, Cepheid's Xpert MRSA/SA SSTI test processes
specimens from suspected skin and soft tissue infection swabs to determine
if a patient is infected with MRSA or SA, giving physicians and surgeons a
powerful new tool to aid in quickly selecting the most effective antibiotic
therapy to improve patient management.

About the GeneXpert(R) System Molecular Diagnostic Platform

The GeneXpert(R) System is a closed, self-contained, fully-integrated
and automated platform that represents a paradigm shift in the automation
of molecular analysis, producing accurate results in a timely manner with
minimal risk of contamination. The GeneXpert System is the only system to
combine on-board sample preparation with real-time PCR (polymerase chain
reaction) amplification and detection functions for fully integrated and
automated nucleic acid analysis. The system is designed to purify,
concentrate, detect and identify targeted nucleic acid sequences thereby
delivering answers directly from unprocessed samples. Modular in design,
the GeneXpert System has a variety of configurations to meet the broad
range of testing demands of any clinical environment.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand
molecular diagnostics company that develops, manufactures, and markets
fully-integrated systems for genetic analysis in the clinical, industrial
and biothreat markets. The company's systems enable rapid, sophisticated
genetic testing for organisms and genetic-based diseases by automating
otherwise complex manual laboratory procedures. The company's easy-to-use
systems integrate a number of complicated and time-intensive steps,
including sample preparation, DNA amplification and detection, which enable
the analysis of complex biological samples in its proprietary test
cartridges. Through its strong molecular biology capabilities, the company
is focusing on those applications where rapid molecular testing is
particularly important, such as identifying infectious disease and cancer
in the clinical market; food, agricultural, and environmental testing in
the industrial market; and identifying bio-terrorism agents in the
biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not
purely historical regarding Cepheid's or its management's intentions,
beliefs, expectations and strategies for the future, including those
relating to product performance, and future market opportunities and market
size. Because such statements deal with future events, they are subject to
various risks and uncertainties, and actual results could differ materially
from the company's current expectations. Factors that could cause actual
results to differ materially include risks and uncertainties such as those
relating to: unforeseen manufacturing problems; regulatory developments and
practices; customer and market acceptance of the product; the failure of
products to perform as expected, whether due to manufacturing errors,
defects or otherwise; the impact of competitive products and pricing;
potentially lengthy sales cycles in some markets; reimbursement rates for
the products; and underlying market conditions worldwide. Readers should
also refer to the section entitled "Risk Factors" in Cepheid's Annual
Report on Form 10-K for 2007 and in its most recent quarterly report on
Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ
included in this release are made as of the date of this press release,
based on information currently available to Cepheid, and Cepheid assumes no
obligation to update any such forward-looking statement or reasons why
results might differ.

(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...

(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...

(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...